Qingyihuaji Formula Inhibits Pancreatic Cancer and Prolongs Survival by Downregulating Hes-1 and Hey-1

HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer

(2015) FENG CAO et al.   ONCOLOGY REPORTS

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer

(2013) Mohamed A. Khalil et al.   INVESTIGATIONAL NEW DRUGS

Targeting Cancer-Related Inflammation: Chinese Herbal Medicine Inhibits Epithelial-to-Mesenchymal Transition in Pancreatic Cancer

(2013) Juan Zhang et al.   PLoS One

Notch3 and Hey-1 as Prognostic Biomarkers in Pancreatic Adenocarcinoma

(2012) Christopher D. Mann et al.   PLoS One

RETRACTED: Notch-1 induces epithelial–mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells

(2011) Bin Bao et al.   CANCER LETTERS

3,5-Bis(2,4-Difluorobenzylidene)-4-piperidone, a Novel Compound That Affects Pancreatic Cancer Growth and Angiogenesis

(2011) D. Subramaniam et al.   MOLECULAR CANCER THERAPEUTICS

Cucurbitacin B, a novel in vivo potentiator of gemcitabine with low toxicity in the treatment of pancreatic cancer

(2010) Gabriela B Iwanski et al.   BRITISH JOURNAL OF PHARMACOLOGY

Targeting Notch to Target Cancer Stem Cells

(2010) A. Pannuti et al.   CLINICAL CANCER RESEARCH

Ski Acts as Therapeutic Target of Qingyihuaji Formula in the Treatment of SW1990 Pancreatic Cancer

(2010) Peng Wang et al.   INTEGRATIVE CANCER THERAPIES

Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabinein vitroand in orthotopic mouse model of human pancreatic cancer

(2010) Kuzhuvelil B. Harikumar et al.   INTERNATIONAL JOURNAL OF CANCER

Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma

(2010) Zeshaan A. Rasheed et al.   JNCI-Journal of the National Cancer Institute

A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model

(2010) N. V. Rajeshkumar et al.   MOLECULAR CANCER THERAPEUTICS

Targeting Notch signaling in pancreatic cancer patients - rationale for new therapy

(2009) P Mysliwiec et al.   Advances in Medical Sciences

Resectable Pancreatic Cancer: Who Really Benefits From Resection?

(2009) Giuliano Barugola et al.   ANNALS OF SURGICAL ONCOLOGY

TW-37, a Small-Molecule Inhibitor of Bcl-2, Inhibits Cell Growth and Induces Apoptosis in Pancreatic Cancer: Involvement of Notch-1 Signaling Pathway

(2009) Z. Wang et al.   CANCER RESEARCH

Acquisition of Epithelial-Mesenchymal Transition Phenotype of Gemcitabine-Resistant Pancreatic Cancer Cells Is Linked with Activation of the Notch Signaling Pathway

(2009) Z. Wang et al.   CANCER RESEARCH

The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism

(2009) Raphael Kopan et al.   CELL

Notch signalling in cancer stem cells

(2009) Victoria Bolós et al.   Clinical & Translational Oncology

Ligand-dependent Notch Signaling Is Involved in Tumor Initiation and Tumor Maintenance in Pancreatic Cancer

(2009) M. E. Mullendore et al.   CLINICAL CANCER RESEARCH

Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer

(2009) Maria–Theresa Mueller et al.   GASTROENTEROLOGY

Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications

(2009) Ivan Ischenko et al.   LANGENBECKS ARCHIVES OF SURGERY

MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells

(2009) Qing Ji et al.   PLoS One